sitagliptin phosphate - Profile

What are the generic drug sources for sitagliptin phosphate and what is the scope of patent protection?

Sitagliptin phosphate is the generic ingredient in two branded drugs marketed by Merck Sharp Dohme, Apotex, Sandoz, and Watson Labs Inc, and is included in four NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Sitagliptin phosphate has fifty-two patent family members in forty countries.

There are fifteen tentative approvals for this compound.

Summary for sitagliptin phosphate

International Patents:	52
US Patents:	1
Tradenames:	2
Applicants:	4
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sitagliptin phosphate

Generic filers with tentative approvals for SITAGLIPTIN PHOSPHATE

Applicant	Application No.	Strength	Dosage Form
		50MG;1000MG	TABLET;ORAL
		50MG;500MG	TABLET;ORAL
		100MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for SITAGLIPTIN PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUVIA	Tablets	sitagliptin phosphate	50 mg/10 mg 50 mg/20 mg 50 mg/40 mg	021995	1	2012-11-06
JANUVIA	Tablets	sitagliptin phosphate	100 mg/20 mg	021995	1	2012-06-25
JANUVIA	Tablets	sitagliptin phosphate	100 mg/10 mg and 100 mg/40 mg	021995	1	2012-06-19
JANUVIA	Tablets	sitagliptin phosphate	25 mg, 50 mg and 100 mg	021995	6	2010-10-18

US Patents and Regulatory Information for sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	AB	RX	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-002	Oct 16, 2006	AB	RX	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	AB	RX	Yes	Yes	7,326,708*PED				Y
Apotex	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202425-001	Jan 20, 2026	AB	RX	No	No
Apotex	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202425-002	Jan 20, 2026	AB	RX	No	No
Apotex	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202425-003	Jan 20, 2026	AB	RX	No	No
Sandoz	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202387-001	Jan 14, 2026	AB	RX	No	No

Expired US Patents for sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	7,078,381
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	7,078,381
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	6,303,661
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	6,890,898
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-002	Oct 16, 2006	6,890,898
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	7,459,428
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	6,303,661

International Patents for sitagliptin phosphate

Country	Patent Number	Title	Estimated Expiration
Denmark	1654263
Montenegro	P60208	SO FOSFORNE KISJELINE I INHIBITORA DIPEPTIDIL PEPTIDAZE-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)
Tunisia	SN05329	PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE -IV INHIBITOR
Ukraine	86026	СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV;СІЛЬ ФОСФОРНОЇ КИСЛОТИ ІНГІБІТОРА ДИПЕПТИДИЛПЕПТИДАЗИ-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)
Australia	2004253889	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
South Africa	200509933	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Morocco	27861	SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (DPP-4)

Supplementary Protection Certificates for sitagliptin phosphate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	C300705	Netherlands		PRODUCT NAME: SITAGLIPTINE; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID
1412357	PA2007006,C1412357	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321
1412357	PA2008013,C1412357	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1084705	CA 2014 00063	Denmark		PRODUCT NAME: SITAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SITAGLIPTIN PHOSPHAT MONOHYDRAT; REG. NO/DATE: EU/1/07/383/001-024 AND EU/1/07/382/001-024 20070321
1412357	C200700039	Spain		PRODUCT NAME: SITAGLIPTINA; NATIONAL AUTHORISATION NUMBER: EU/1/07/383/001-018; DATE OF AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001-018; DATE OF FIRST AUTHORISATION IN EEA: 20070321

Sitagliptin Phosphate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Sitagliptin phosphate, marketed primarily under the brand Januvia by Merck & Co., is a leading oral antihyperglycemic agent indicated for Type 2 Diabetes Mellitus (T2DM). Since its FDA approval in 2006, the drug has established a robust market presence, with continuous expansion fueled by rising diabetes prevalence, innovative combination therapies, and strategic patent management. This report analyzes sitagliptin's investment landscape, market dynamics, and projected financial trajectories, emphasizing key factors influencing growth, competitive positioning, and revenue potential through 2030.

---

1. Investment Scenario: Valuation, Opportunities, and Risks

1.1 Current Market Valuation

• Market Capitalization & Revenue: As of 2022, Merck’s diabetes portfolio, predominantly driven by sitagliptin, contributed approximately $4.9 billion globally. Janumet (sitagliptin + metformin) accounted for an estimated $3.2 billion (IQVIA, 2022).
• Patent Status & Regulatory Exclusivity: The primary patent for Januvia expired in 2029 in key markets like the US and the EU, pushing the company toward biosimilar competition and patent cliff effects.

1.2 Investment Opportunities

• Emerging Markets Expansion: Increased diabetes cases in Asia-Pacific—expected to grow at a CAGR of 7%—present high-growth opportunities.
• New Formulations & Combinations: Development of fixed-dose combinations (FDCs) enhances adherence and therapeutic efficacy, opening avenues for premium pricing.
• Biosimilar & Generic Competition: Entry of generics post-patent expiry could secularly erode revenues but also offers licensing, partnership, or acquisition opportunities for strategic investors.

1.3 Risks and Challenges

Risk Type	Description	Mitigation Strategies
Patent Expiration	Revenue decline post-2029 with biosimilar entry	Diversify pipeline; seek novel formulations
Market Competition	Competition from other DPP-4 inhibitors (Onglyza, Tradjenta)	Innovate via combination therapies
Regulatory Hurdles	Approval delays or restrictions in emerging markets	Early engagement with regulators
Pricing & Reimbursement	Price pressures in mature markets	Demonstrate cost-effectiveness
Patent Litigation	Legal disputes affecting exclusivity	Experienced legal counsel; patent defense

---

2. Market Dynamics Analysis

2.1 Global Market Size & Growth Trends

Year	Global Diabetes Market ($B)	Sitagliptin Market Share	CAGR (2018-2027)	Notes
2022	$62	~8% (approx. $5B)	7-8%	Dominant among oral antidiabetics
2027	$98	Projected $8-$10B		Driven by rising T2DM prevalence

• Forecasts indicate a compound annual growth rate (CAGR) of approximately 7% from 2022 to 2027.

2.2 Key Market Drivers

• Rising prevalence of T2DM: Over 460 million affected worldwide (International Diabetes Federation, 2021).
• Increased health awareness: Screening leads to earlier diagnosis and treatment.
• Therapeutic positioning: Oral medications preferred over injectables in many regions.
• Policy & reimbursement optimizations: Favorable coverage for combination agents.

2.3 Competitive Landscape

Competitors	Key Features	Market Share (Estimated, 2022)
Onglyza (saxagliptin)	DPP-4 inhibitor, marketed by AstraZeneca	~5%
Tradjenta (linagliptin)	DPP-4 inhibitor, by Boehringer Ingelheim	~4%
Vildagliptin (Market in EU, generic in others)	High availability at lower cost	~3%
Biosimilars	Expected to impact in 2029+	Emerging

2.4 Regulatory & Policy Influences

• FDA’s 2020–2030 diabetes management guidelines increasingly favor combination therapies with proven cardiovascular benefits.
• Healthcare reforms in emerging markets aim to improve access, potentially increasing sitagliptin adoption.
• Patent cliffs in 2029 will reshape market shares, emphasizing pipeline diversification.

---

3. Financial Trajectory and Forecasts

3.1 Revenue Projections (2023–2030)

Year	Estimated Revenue ($B)	Assumptions & Drivers
2023	$4.7	Post-patent expiry, generic competition begins in US
2025	$3.5	Generics eroding branded sales; growth elsewhere offset slightly
2027	$2.8	Market saturation; biosimilar competition intensifies
2029	$1.2	Patent expiry leading to significant decline
2030	$1.0 (or lower)	Stabilization with biosimilar presence

Note: The forecast assumes gradual erosion of patent exclusivity and robust growth in emerging markets.

3.2 Major Revenue Streams

Stream	Share of Revenue (2022)	Dynamics
Original sitagliptin (Januvia)	~60%	Declining trend post-2029
Fixed-dose combinations (e.g., Janumet)	~25%	Growth with new formulations; patent expirations affect this
Biosimilars & Generics	N/A (post-2029)	Likely to dominate post-patent expiry

3.3 Investment Considerations

• Short-term: Opportunities in emerging markets and new formulations.
• Medium-term: Risk mitigation via pipeline expansion into GLP-1 receptor agonists and SGLT2 inhibitors.
• Long-term: Transition towards biosimilars, generics, and novel oral agents; strategic alliances essential.

---

4. Comparative Analysis with Competitors

Attribute	Sitagliptin (Januvia)	Other DPP-4 Inhibitors	SGLT2 Inhibitors	GLP-1 Receptor Agonists
Market Launch	2006	2007–2013	2013–2018	2005–2018
Patent Expiry	2029 (US/EU)	Similar in some cases	2027–2029	2029 (in some markets)
Revenue (2022)	~$3.2B (Janumet included)	Varies (~$2B –$4B)	~$4B	~$3B
Combination Potential	High (with metformin, others)	High	Moderate (with other agents)	Moderate (with other agents)

---

5. Strategic Positioning & Investment Recommendations

• Leverage emerging market growth: Expand access and commercialization in Asia, Africa, Latin America.
• Invest in pipeline diversification: Focus on expanding into SGLT2 and GLP-1 classes.
• Prepare for biosimilar integration: Early engagement with biosimilar developers and patent attorneys.
• Explore licensing opportunities: Out-licensing formulations or combination therapies in markets where patent exclusivity wanes.

---

6. Deep Dive: Regulatory & Patent Policies Impacting Investment

Policy Aspect	Implication for Sitagliptin	Description
Patent Term & Extensions	Patent expiry 2029 in US/EU; potential extensions	US and EU patents generally last 20 years from filing, with possible extensions for regulatory delays.
Patent Challenge & Litigation	Risk in succeeding years	Patent disputes could delay biosimilar entry.
Regulatory Pathways	Accelerated approvals for biosimilars	Use of regulatory pathway incentives could influence time-to-market for generics.
Price Regulation Policies	Possible price caps in emerging markets	May suppress revenue in certain jurisdictions.

---

7. Key Takeaways

• Market leadership: Sitagliptin remains a key player in T2DM management with a significant revenue base, though facing post-2029 patent expiry risks.
• Growth opportunities: Emerging markets, combination therapies, and pipeline expansion sustain long-term growth potential.
• Competitive landscape: Increasing competition from biosimilars, generics, and next-generation agents necessitates strategic innovation and partnerships.
• Financial trajectory: Revenue peaks are anticipated before 2029; substantial declines expected post-patent expiry, emphasizing the importance of pipeline diversification.
• Investment strategy: Diversify holdings in emerging markets, focus on pipeline expansion, and anticipate biosimilar competition to optimize returns.

---

FAQs

1. When will sitagliptin phosphate patents expire, and how will that affect revenues?

The primary patent for sitagliptin phosphate, marketed as Januvia, is set to expire in 2029 in major markets like the US and EU. Post-expiry, biosimilar and generic competitors are expected to enter, potentially eroding revenues significantly. Strategic planning around patent cliffs involves pipeline expansion and formulation innovation.

2. How do emerging markets influence sitagliptin's investment outlook?

Emerging markets such as China, India, and Southeast Asia present high-growth opportunities due to increasing diabetes prevalence, expanding healthcare coverage, and lower market penetration. These regions can offset revenue declines in mature markets and offer licensing or partnership prospects.

3. What role will biosimilars play in the future for sitagliptin?

Biosimilars are expected to dominate the post-2029 landscape, providing cost-effective alternatives. Early engagement with biosimilar developers and strategic moves like licensing, co-marketing, or acquisitions can mitigate revenue erosion.

4. How does combination therapy influence sitagliptin's market share?

Fixed-dose combinations (e.g., Janumet, sitagliptin + SGLT2 inhibitors or GLP-1 agonists) enhance adherence and therapeutic efficacy. They account for approximately 25% of current revenues and are expected to grow, reinforcing sitagliptin's market positioning.

5. What are the primary risks for investors considering sitagliptin-related assets?

Key risks include patent expiry-induced revenue decline, intensifying competition, regulatory hurdles, and pricing pressures. Managing these risks requires pipeline diversification, geographic expansion, and strategic alliances.

---

References

1. IQVIA. (2022). Pharmaceutical Market Analysis.
2. International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.
3. U.S. Food and Drug Administration. (2006). FDA Approval of Sitagliptin.
4. European Medicines Agency. (2020). Reflections on Patent and Market Dynamics.
5. MarketsandMarkets. (2022). Diabetes Market by Therapeutic Class and Region.